Please login to the form below

Not currently logged in
Email:
Password:

Akcea Pharma

This page shows the latest Akcea Pharma news and features for those working in and with pharma, biotech and healthcare.

Pfizer pays $250m upfront to Akcea for phase 2 antisense drug

Pfizer pays $250m upfront to Akcea for phase 2 antisense drug

affiliate. The big pharma – which has traditionally relied on acquisitions and licensing deals to keep its pipeline stocked – is paying $250m upfront for rights to AKCEA-ANGPTL3-LRx, an antisense oligonucleotide ... The Swiss pharma group took an

Latest news

  • Akcea gets first OK for Waylivra in rare triglyceride disorder Akcea gets first OK for Waylivra in rare triglyceride disorder

    EU becomes the first market for the new drug. Akcea has been granted a conditional approval for Waylivra, its antisense drug for rare inherited disorder familial chylomicronemia syndrome (FCS), in Europe. ... In Europe, Akcea has committed to a

  • Akcea steals march on Alnylam with NICE approval Akcea steals march on Alnylam with NICE approval

    Advantage to Tegsedi over Onpattro. NICE has recommended Akcea Therapeutics’ rare disease treatment Tegsedi (inotersen), after the company improved its price offer. ... Richard A. Jones,  SVP Head of Europe for Akcea Therapeutics. “hATTR amyloidosis

  • Despite FDA concerns, Akcea rare disease drug clears FDA panel Despite FDA concerns, Akcea rare disease drug clears FDA panel

    FDA now set to deliver final verdict by 30 August. Akcea Pharma has moved a step closer to commercialising Waylivra, a drug for rare disorder familial chylomicronemia syndrome (FCS), after an ... We believe that these results provide strong support to

  • Novartis boosts cardiovascular pipeline with $1bn Ionis deal Novartis boosts cardiovascular pipeline with $1bn Ionis deal

    The new agreement with Ionis subsidiary Akcea Pharma gives Novartis an option to license the two lipoprotein-targeting drugs, which are in early-stage clinical development. ... Novartis is also expected to make a further equity investment of $50m in the

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics